As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse

Eldelumab is a monoclonal antibody designed for the treatment of Crohn's disease and ulcerative colitis.

As an industrial leader in antibody-drug conjugate (ADC) development and with our experienced science teams, Creative Biolabs provides the most comprehensive cysteine-based conjugation approaches to generate highly customized ADCs in a timely.

Several groups hypothesized that it may be necessary to construct ADCs with drugs of much higher molar potencies than conventional chemotherapeutics to achieve therapeutically effective levels of active drug within tumors in patients.

Mertansine, the cytotoxic component in antibody-drug conjugates, attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimidyl 4-(2-pyridyldithio)) linker or SMCC (4-(3-mercapto-2,5-dioxo-1 pyrrolidinylmethyl)-cyl

Creative Biolabs offers a variety of chemically versatile linker molecules to facilitate antibody-drug conjugate (ADC) development projects. All chemical linkers are of >95% purity and they are the basic building blocks for a successful ADC.

Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents that are constructed by the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. As a key factor in an ADC, the payload d

The two most common naturally occurring amino acids that are used to attach the linker drug to the antibody are cysteines and lysines.

Description: Vasopressin, also known as arginine vasopressin (AVP), antidiuretic hormone (ADH), or argipressin, is a neurohypophysial hormone found in most mammals. Its two primary functions can retain water in the body and to constrict blood vesse

Linker design for ADCs is highly dependent on the biolology of the target cells, the characteristics of the antibody, and the structure of the drug molecule. Selection of the optimal linker is achieved through efficacy and toxicity assessments for ea